For Francine Prose, an amusement-park trip as a young girl led to a ride on the Spook-a-Rama and later to a prized Diane Arbus photo of the same ride.
NYS Entity Status
NYS Filing Date
MARCH 27, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2014 - ALL ISLAND POINT OF SALE INC.
AROUND THE WEB
- SUMMER FIRSTS | Brooklyn: Finding Alchemy and Art on a Coney Island Scary Ride
By FRANCINE PROSE - Wednesday Aug 2, 2017
- New York Today: New York Today: New Subway Clocks
By JONATHAN WOLFE - Monday Aug 7, 2017
Monday: Rolling out new subway clocks, the Corkscrew Theater Festival, and National Lighthouse Day.
- Under the Stars and Quilts, With Randalls Island as Her Stage
By GIA KOURLAS - Friday Aug 11, 2017
For her newest performance project, the dance artist Emily Johnson will gather 300 people for an all-night event.
- For 18 Hours, Cabbie Sat Dead in Front Seat
By KIM BARKER - Monday Aug 14, 2017
A driver parked his taxi to take a break in SoHo. He died behind the wheel. Then, for nearly a day, New Yorkers went about their lives — just feet from his body.
- Sunday Routine: How Helen Uffner, Vintage Clothing Expert, Spends Her Sundays
By ABIGAIL MEISEL - Friday Aug 11, 2017
She’s found retro outfits for Meryl Streep and Kate Winslet. On Sundays, the period clothing specialist visits flea markets and estate sales.
- Abbvie’s hep C drug pricing threatens Gilead’s dominance
By Max Nisen - Tuesday Aug 8, 2017
Pharma already leads the business world in unpredictability, with billions in sales potentially riding on a few points of statistical significance in a clinical trial.[...] even within that context, a series of blockbuster medicines for hepatitis C have made for a roller-coaster ride for companies and investors.AbbVie Inc. last week threw another big curve at this market by pricing its newly FDA-approved drug Mavyret — which might be the most effective hepatitis C medicine approved yet — at a massive discount.Medicines from Johnson & Johnson, Merck & Co. Inc. and Vertex Pharmaceuticals Inc. approved within the past six years, which once booked billions in combined sales, are now essentially non-factors.After offering behind-the-scene discounts to insurance companies, pharmacy benefit managers and other payers, Mavyret’s price is actually not far from Harvoni’s, according to Bloomberg Intelligence.The real headache for Gilead — which already faces steep declines in hepatitis C drug sales because of increasing competition and the fact that many patients have been cured — lies in the fact that not all hepatitis patients or medicines are the same.AbbVie’s new drug can treat all of the major subtypes of hepatitis C. And it can cure the disease in many patients in just eight weeks.